YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
MediLink Therapeutics (Suzhou) Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Hutchmed
CSPC Megalith Biopharmaceutical Co.,Ltd.
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Sun Yat-sen University
Sun Yat-sen University
GlaxoSmithKline
Fudan University
Genfleet Therapeutics (Shanghai) Inc.
Helsinki University Central Hospital
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Fudan University